A change from subcutaneous to intravenous erythropoietin increases the cost of anemia therapy

Nephron - Clinical Practice

Volumn 107, Issue 3, 2007, Pages

  McFarlane, Philip A ^a   Hillmer, Michael P ^b   Dacouris, Niki ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anemia, drug therapy; Cost analysis; Erythropoietin; Injections; Intravenous; Subcutaneous

Indexed keywords

ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; FERROUS FUMARATE; FERROUS GLUCONATE; FERROUS SULFATE; IRON;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; COST BENEFIT ANALYSIS; DEMOGRAPHY; FEMALE; HEMODIALYSIS; HUMAN; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; ANEMIA; ERYTHROPOIETIN; FEMALE; HEALTH CARE COSTS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MODELS, ECONOMIC; ONTARIO;

EID: 35948964378     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000108649     Document Type: Article

References (12)

1. Lee H, Manns B, Taub K, Ghali WA, Dean S, Johnson D, Donaldson C: Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis 2002;40:611-622.
2. McFarlane PA, Pierratos A, Redelmeier DA: Cost savings of home nocturnal versus conventional in-center hemodialysis. Kidney Int 2002;62:2216-2222.
3. Besarab A, Reyes CM, Hornberger J: Metaanalysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:439-446.
4. Kaufman JS: Subcutaneous erythropoietin therapy: efficacy and economic implications. Am J Kidney Dis 1998;32:S147-S151.
5. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA: Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs cooperative study group on erythropoietin in hemodialysis patients. N Engl J Med 1998;339:578-583.
6. Ashai NI, Paganini EP, Wilson JM: Intravenous versus subcutaneous dosing of epoetin: a review of the literature. Am J Kidney Dis 1993;22:23-31.
7. Moist LM, Muirhead N, Wazny LD, Gallo KL, Heidenheim AP, House AA: Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis. Ann Pharmacother 2006;40:198-203.
8. Mercadal L, Sutton L, Casadevall N, Bagnis C, Jacobs C: Immunological reaction against erythropoietin causing red-cell aplasia. Nephrol Dial Transplant 2002;17:943.
9. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-475.
10. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001;37:S182-S238.
11. Summary of PRCA case reports: update on the actions by Johnson & Johnson pharmaceutical research & development regarding erythropoietin antibody-positive pure red cell aplasia. Accessed March 23rd 2007. http://www.jnjpharmarnd.com/company/ncasereports.html.
12. Lim LC: Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure. Hematology 2005;10:255-259